FFO
CPRX

Fortitude Family Office’s Catalyst Pharmaceutical CPRX Stock Holding History

Fortitude Family Office’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.63K Hold
106
– – ﹤0.01% 1184
2025
Q4 		$2.47K Hold
106
– – ﹤0.01% 1088
2025
Q3 		$2.09K Hold
106
– – ﹤0.01% 1200
2025
Q2 		$2.3K Sell
106
-11
-9% -$260 ﹤0.01% 1125
2025
Q1 		$2.84K Hold
117
– – ﹤0.01% 858
2024
Q4 		$2.44K Hold
117
– – ﹤0.01% 1002
2024
Q3 		$2.33K Hold
117
– – ﹤0.01% 973
2024
Q2 		$1.81K Hold
117
– – ﹤0.01% 817
2024
Q1 		$1.86K Hold
117
– – ﹤0.01% 833
2023
Q4 		$1.97K Buy
+117
New +$1.6K ﹤0.01% 872

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fortitude Family Office's CPRX Position: Q1 2026 in Review

Fortitude Family Office held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 106 shares worth $2.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1184.

Fortitude Family Office first reported a position in CPRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.84K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Fortitude Family Office held 106 shares of Catalyst Pharmaceutical worth $2.63K as of Q1 2026.
  • Fortitude Family Office left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1184 holding.
  • Fortitude Family Office first reported a position in Catalyst Pharmaceutical in Q4 2023 and has held it in 10 quarters since.
  • Fortitude Family Office's Catalyst Pharmaceutical position peaked at $2.84K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.